Deutsche Bank
SYRS

Deutsche Bank’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Deutsche Bank’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,316
Closed -$39K – 4363
2022
Q1 		$39K Sell
3,316
-372
-10% -$6.65K ﹤0.01% 3913
2021
Q4 		$120K Sell
3,688
-2,309
-39% -$93.5K ﹤0.01% 3629
2021
Q3 		$268K Buy
5,997
+2,381
+66% +$116K ﹤0.01% 3415
2021
Q2 		$196K Sell
3,616
-2,003
-36% -$119K ﹤0.01% 3800
2021
Q1 		$420K Buy
5,619
+2,513
+81% +$261K ﹤0.01% 3213
2020
Q4 		$337K Buy
3,106
+802
+35% +$73.2K ﹤0.01% 3164
2020
Q3 		$204K Buy
2,304
+201
+10% +$22.8K ﹤0.01% 3202
2020
Q2 		$224K Buy
2,103
+913
+77% +$82K ﹤0.01% 3090
2020
Q1 		$70K Sell
1,190
-725
-38% -$49.2K ﹤0.01% 3400
2019
Q4 		$131K Sell
1,915
-3,917
-67% -$238K ﹤0.01% 3453
2019
Q3 		$604K Sell
5,832
-3,249
-36% -$307K ﹤0.01% 2582
2019
Q2 		$838K Buy
9,081
+6,107
+205% +$425K ﹤0.01% 2961
2019
Q1 		$269K Sell
2,974
-1,601
-35% -$112K ﹤0.01% 3823
2018
Q4 		$254K Sell
4,575
-2,933
-39% -$223K ﹤0.01% 3744
2018
Q3 		$894K Sell
7,508
-13,343
-64% -$1.55M ﹤0.01% 3412
2018
Q2 		$2.13M Buy
20,851
+18,857
+946% +$2.34M ﹤0.01% 2910
2018
Q1 		$258K Sell
1,994
-767
-28% -$83.9K ﹤0.01% 4061
2017
Q4 		$267K Sell
2,761
-788
-22% -$106K ﹤0.01% 3895
2017
Q3 		$520K Buy
3,549
+2,081
+142% +$391K ﹤0.01% 3400
2017
Q2 		$234K Buy
1,468
+1,353
+1,177% +$213K ﹤0.01% 3846
2017
Q1 		$18K Sell
115
-190
-62% -$23.2K ﹤0.01% 4534
2016
Q4 		$35K Buy
+305
New +$42.8K ﹤0.01% 4449

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank's SYRS Position: Q2 2022 in Review

Deutsche Bank sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 3,316 shares — an estimated $39K sold.

Deutsche Bank first reported a position in SYRS in Q4 2016 and held it in 22 quarters. The position peaked at $2.13M in Q2 2018. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • Deutsche Bank reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 3,316 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $39K.
  • Deutsche Bank first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 22 quarters.
  • Deutsche Bank's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.13M in Q2 2018.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.